Upstream Bio, Inc. (UPB) — Analyst outlook / Analyst consensus target is. Based on 1 analyst ratings, the consensus is neutral — 1 Hold.
The consensus price target is $49.00 (low: $47.00, high: $51.00), representing an upside of 396.5% from the current price $9.87.
Analysts estimate Earnings Per Share (EPS) of $-8.03 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2025: actual $-2.66 vs est $-2.60 (missed -2.5%). Analyst accuracy: 98%.
UPB Stock — 12-Month Price Forecast
$49.00
▲ +396.45% Upside
Average Price Target
Based on 1 Wall Street analysts offering 12-month price targets for Upstream Bio, Inc., the average price target is $49.00, with a high forecast of $51.00, and a low forecast of $47.00.
The average price target represents a +396.45% change from the last price of $9.87.
Highest Price Target
$51.00
Average Price Target
$49.00
Lowest Price Target
$47.00
UPB Analyst Ratings
Hold
Based on 1 analysts giving stock ratings to Upstream Bio, Inc. in the past 3 months
EPS Estimates — UPB
98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.00
vs Est –$8.03
▲ 0.0% off
2025
Actual –$2.66
vs Est –$2.60
▼ 2.4% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — UPB
92%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.002B
vs Est $0.002B
▲ 9.2% off
2025
Actual $0.003B
vs Est $0.003B
▲ 6.6% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
